Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5016698 | 0.98 | TACR2 (0.66) | TACR2TACR1 | |
| Acetic Acid SCHEMBL5015222 | 0.90 | TACR2 (0.61) | TACR2TACR1 | |
| Acetic Acid SCHEMBL4268550 | 0.89 | TACR2 (0.67) | TACR2TACR1 | |
| SCHEMBL13754779 | 0.87 | TACR2 (0.61) | TACR2TACR1 | |
| SCHEMBL6002529 | 0.86 | TACR2 (0.68) | TACR2TACR1 | |
| SCHEMBL5013640 | 0.86 | TACR2 (0.68) | TACR2TACR1 | |
| Acetic Acid SCHEMBL4413705 | 0.81 | TACR2 (0.52) | TACR2TACR1 | |
| Acetic Acid SCHEMBL4266480 | 0.81 | TACR2 (0.65) | TACR2TACR1 | |
| Acetic Acid SCHEMBL5013685 | 0.79 | TACR2 (0.48) | TACR2TACR1 | |
| SCHEMBL493662 | 0.79 | TACR2 (1.00) | TACR2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417142-B2 | Chiral porphyrins, chiral metalloporphyrins, and methods for synthesis of the same | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7402581-B2 | Azetidine compounds | ALBIREO AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20060172988-A1 | Azetidine compounds | ALBIREO AB (SE) | 2006-08-03 | — | — | US | disclosed |
| EP-1636221-A2 | NEW AZETIDINE COMPOUNDS | AstraZeneca AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| US-20060030718-A1 | Cobalt-based catalysts for the cyclization of alkenes | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-02-09 | — | — | US | disclosed |
| US-20050124596-A1 | Chiral porphyrins, chiral metalloporphyrins, and methods for synthesis of the same | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2005-06-09 | — | — | US | disclosed |
| WO-2004110344-A2 | NEW AZETIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030718-A1 | Cobalt-based catalysts for the cyclization of alkenes | PPOX, HCCS, ICOSLG | TACR2 3231/4885TACR1 4192/4885 |
| US-20060172988-A1 | Azetidine compounds | HRH2, HRH4, HRH1 | TACR2 19/4885TACR1 28/4885 |
| US-20050124596-A1 | Chiral porphyrins, chiral metalloporphyrins, and methods for synthesis of the same | PPOX, PPIF, HMBS | TACR2 2573/4885TACR1 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.